A year ago, DOJ moved to dismiss 11 qui tam False Claims Act actions brought by Venari Partners, LLC (doing business as National Health Care Analysis Group), over NHCA’s objections. Those motions, together with DOJ’s promise in late November 2018 to dismiss Gilead Sciences, Inc. v. United States ex rel. Campie on remand from the Supreme Court, were an indication that DOJ was executing on the Granston Memo’s directive to seek dismissals of meritless and burdensome qui tam cases. Decisions have now been issued in all 11 cases. And while courts adopted different views as to the appropriate standard of review, 10 of the 11 cases ultimately were dismissed.
Regulations, Compliance, & Enforcement
Trending Now
5 Strategies to Reduce the Risk of a DOJ False Claims Act Investigation • DOJ Announces Enforcement Priorities for National Fraud Enforcement Division • Second Circuit Clarifies Scope of “Property” that an FCA “Claim” May Seek • Could AI Use Waive Privilege in Your Internal Investigation? • Rhodes to Exit as OFPP Administrator
Granston Motions Prove to be Effective Tools Against Professional Relator in Nurse Educator Cases
rawf8 | Shutterstock
Track False Claims Act cases, audit trends, and compliance best practices with our Compliance & Enforcement newsletter, delivering up-to-the-minute intelligence Monday–Saturday — Subscribe here.